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It is very rewarding for endocrine pathologists to see, in 
the new book of the World Health Organization (WHO) 
classification of endocrine organs 1, how the molecular 
characterization of thyroid tumours has confirmed the 
types and subtypes of tumours previously recognized 
by less sophisticated techniques. The cribriform-mor-
ular variant of papillary thyroid carcinoma (PTC) is a 
paradigmatic example of this close correlation between 
the classical morphological aspects and genetic-mo-
lecular alterations. In fact, this morphological-molecular 
correlation in the cribriform-morular variant of PTC is 
so distinctive that we have recently found that cribri-
form-morular thyroid carcinoma is a more appropriate 
denomination 2. In this brief article, we summarize the 
main features that have justified this new designation.
After the first descriptions of associations between 
thyroid tumours and familial adenomatous polyposis 
(FAP) (for a review, see Cameselle-Teijeiro et al.)  2, 
it was Harach et al. 3 who first recognized the unusu-
al histological features of thyroid tumours that were 
commonly multifocal and predominantly occurring 
in young women in the setting of FAP. Later, Came-
selle-Teijeiro and Chan  4 proposed the name of cri-
briform-morular variant of PTC, for morphologically 
similar sporadic tumours that usually occur as single 
nodules in patients with no germline APC gene muta-
tion (without FAP). Now, as a consequence, we know 
that clinicians should be alerted to the possibility of 
FAP when a case of cribriform-morular thyroid carci-
noma is diagnosed 3.
Cribriform-morular thyroid carcinomas are usually 
well-delimited neoplasms microscopically showing a 
blending of cribriform, papillary, follicular, solid and 
trabecular patterns with squamoid morules 2-5 (Fig. 1). 
Cribriform and follicular structures lack colloid, and 
solid areas are composed of oval to spindle cells. Pa-
pillae are lined by tall or cuboidal cells with occasion-
al nuclear features of conventional PTC and frequent 
nuclear pseudostratification. Morules with biotin-rich 
clear nuclei but without keratinization can appear in 
variable proportions in cribriform, follicular, papillary, 
solid and/or trabecular areas. This is the only prima-
ry thyroid tumour with strong nuclear and cytoplas-
mic immunoreactivity for β-catenin  2  5. Tumour cells 
are negative or focally positive for thyroglobulin, but 
always positive for thyroid transcription factor 1 (TTF-
1) and negative for calcitonin. There is characteristic 
positivity for alpha and beta-estrogen and progester-
one receptors, cytokeratin (CK) 7, CK 19 and negativ-
ity for CK 20. Morules are also positive for β-catenin 
and can easily be distinguished by their positivity for 
CD10, CA19.9 and CDX2, an intestine-specific home-
obox gene transcription factor.
In fine needle aspiration biopsy the cytological sam-
ples are hypercellular and usually show nuclear fea-
tures of conventional papillary thyroid carcinoma, but 
the presence of cribriform and/or morular structures, 
as well as the nuclear positivity for β-catenin are 
highly indicative of cribriform-morular thyroid carci-
noma 2 5.
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In normal follicular cells the APC protein, along with 
axin, glycogen synthetase kinase 3β (GSK3β) and 
casein kinase 1α (CK1α), forms a destruction com-
plex that maintains the cytoplasmic concentrations of 
β-catenin low. The characteristic positivity for β-cat-
enin in familial cases of cribriform-morular thyroid car-
cinoma results from the permanent activation of the 
wingless (WTN/β-catenin) signaling pathway second-
ary to germline APC gene mutations. In these cas-
es β-catenin accumulates in the cytoplasm and then 
is translocated into the nucleus where it produces 
the constitutive expression of genes such as MYC, 
CCND1 (cyclin D1), Axin2 and DKK1, involved in cell 
proliferation and loss of differentiation2. Consistent 
with Knudson’s two-hit model, additional APC somat-
ic mutations have also been found in about 50% of 
thyroid carcinomas associated with FAP. Interestingly, 
the diagnosis of cribriform-morular thyroid carcinoma 
is prior to a diagnosis of FAP in up to 40% of cas-
es  2 6. Because most germline APC mutations relat-
ed to thyroid cancer occur in the same genomic area 
associated with congenital hypertrophy of the retinal 
pigmented epithelium, fundoscopy is a good clinical 
approach to confirm the germline APC mutation while 
awaiting genetic studies 5.
In sporadic cribriform-morular thyroid carcinomas, so-
matic APC gene mutations (exon 15 at codon 1309) 
with a negative dominant effect, or combinations 
of somatic mutations in phenotypically equivalent 
genes such as CTNNB1 and AXIN1 are involved in 
the constitutive activation of the WTN/β-catenin path-
way. Although BRAF gene mutations have not been 
found in these tumours, it has been proposed that the 
presence of RET/PTC1 and RET/PTC3 rearrange-
ments, as well as mutations in PIK3CA and K-RAS 
genes, could also act as additional upstream effec-
tors in the WTN/β-catenin pathway  2  7. The striking 
predominance of this tumour in young women (ratio 
female-male of 61:1) fits with the strong positivity for 
alpha and beta-estrogen receptors and progesterone 
Fig. 1. Cribriform-morular thyroid carcinoma showing a predominant cribriform pattern (A), and strong nuclear and cyto-
plasmic immunoreactivity for β-catenin (B). The morules are positive for CD10 (C).
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receptors in tumour cells, and additionally suggests a 
promoter growth role for sex hormones in the devel-
opment of this tumour type  2  5. This neoplasm gen-
erally has a good prognosis, but neuroendocrine dif-
ferentiation 8, poorly differentiated features (including 
high Ki-67 labeling index) 9 and/or telomerase reverse 
transcriptase (TERT) promoter mutations 10 may help 
to predict more aggressive clinical behaviour in cribri-
form-morular thyroid carcinomas. 
Cribriform-morular thyroid carcinoma is a distinctive 
neoplasm that seems to emerge from endodermal 
non-committed follicular cells. In this rare thyroid tu-
mour, the constitutive activation of the WTN/β-catenin 
pathway justifies its primitive intestinal-like appear-
ance. Its peculiar clinicopathological and molecular 
features support its consideration as an independent 
tumour entity. 
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